Vor Biopharma Inc.
NASDAQ Global SelectTotal Valuation
Vor Biopharma Inc. carries a market capitalization of 977.51M, placing it among publicly traded companies globally. Its enterprise value stands at 539.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 977.51M |
| Enterprise Value | 539.28M |
Share Statistics
Vor Biopharma Inc. currently has 54.46M shares outstanding.
| Shares Outstanding | 54.46M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Vor Biopharma Inc. trades at a trailing price-to-earnings ratio of 1.02.
| PE Ratio | 1.02 |
| PS Ratio | N/A |
| PB Ratio | -5.01 |
| P/TBV Ratio | -5.01 |
| P/FCF Ratio | -4.58 |
| P/OCF Ratio | -4.56 |
Financial Position
Vor Biopharma Inc. maintains a current ratio of 19.15, meaning it holds 19.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 19.15 |
| Quick Ratio | 18.78 |
| Debt / Equity | -1.44 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 182.91 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -73.73 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Vor Biopharma Inc.'s stock has declined approximately -38.702% over the past 52 weeks. The 50-day moving average sits at 21.43, while the 200-day moving average is 17.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | -38.702% |
| 50-Day Moving Average | 21.43 |
| 200-Day Moving Average | 17.05 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -146.99M, while operating income came in at -147.08M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -147.08M |
| Pretax Income | 627.78M |
| Net Income | 627.78M |
| EBITDA | -146.99M |
| EBIT | -147.08M |
| Earnings Per Share (EPS) | 18.11 |
Balance Sheet
Vor Biopharma Inc. holds 466.13M in cash and equivalents against 2.88M in total debt, resulting in a net debt position of -107.85M. Total book value stands at -200.20M, with working capital of 450.29M providing operational flexibility.
| Cash & Cash Equivalents | 466.13M |
| Total Debt | 2.88M |
| Net Debt | -107.85M |
| Equity (Book Value) | -200.20M |
| Book Value Per Share | -3.68 |
| Working Capital | 450.29M |
Cash Flow
Vor Biopharma Inc. produced -140.09M in operating cash flow over the past twelve months. After subtracting -726,000.00 in capital expenditures, free cash flow totaled -140.81M - equivalent to -4.06 per share.
| Operating Cash Flow | -140.09M |
| Capital Expenditures | -726,000.00 |
| Free Cash Flow | -140.81M |
| FCF Per Share | -4.06 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -40.31 |
| FCF Yield | -21.84 |
Stock Splits
Vor Biopharma Inc.'s most recent stock split took place on September 19, 2025 with a 20:1 split ratio.
| Last Split Date | 9/19/2025 |
| Split Ratio | 20:1 |
Scores
Vor Biopharma Inc. posts an Altman Z-Score of -3.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.18 |